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ABSTRACT 
Objective: Novel COVID-19 virus is extensively being studied for its long-term effects. A predominant trend of development of Diabetes Mellitus 
(DM) in Covid-19 patients is being observed, and hence further relation is explored in this study. 
Methods: This is an observational inductive retrospective study conducted for four months in a tertiary care hospital. The study included subjects 
who recovered from COVID-19 and were treated post-COVID-19 in the hospital. The subjects who had stable glucose counts were excluded. The 
data obtained from the medical record department encompassed demographic details and clinical data of the patient. The data were tabulated, and 
observations were reported using descriptive analysis. 
Results: Among 5632 admitted patients for COVID-19, 694 came for follow-up. 105 patients were re-admitted, but 11 had newly developed DM, and 
14 observed uncontrolled DM managed by medical attention. The reported incidence rate in Newly-Diagnosed DM was 0.195%, and the person 
above 41 y was at greater risk. Similarly, the incidence rate in Uncontrolled-DM was 13.33%, and persons above 47 y were at greater risk. It was 
found that both these categories of patients had comorbidities, and the development of this was seen between the 25th-40th day. In both cases, 
males were more prone than females. 
Conclusion: The study reports a bi-directional relationship between Covid-19 and DM. The use of steroids may have stepped-up this relationship. 
Cautious use of steroids, changes in the hospital formulary, and further quantitative clinical investigations are primary recommendations that may 
prevent such episodes. 
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INTRODUCTION 
Covid-19, being a relatively recent virus, has much scope and research 
for analysis. Evidence regarding COVID-19 has yet been emerging, and 
current information has given researchers the latest perspective 
regarding it. Such is observed as a relationship between Covid-19 and 
Diabetes Mellitus. This newly observed relationship between Diabetes 
Mellitus and COVID-19 is initially seen as increased Blood glucose 
levels followed by other clinical symptoms [1, 2]. 
It is important to note a peculiar relationship between age and the 
commencement of Diabetes Mellitus [3]. Individuals with Diabetes 
Mellitus, Hypertension, and severe Obesity (BMI less than 40 
kg/m2) are more likely to be infected. They are at higher risk for 
complications and death from COVID-19 [4]. Investigations using 
meta-analysis or double-blinded methods have been used so far to 
objectively examine the relationship [5]. Between COVID-19 and 
Diabetes, there is a bidirectional/relationship [6]. Diabetes is linked 
to a higher risk of extreme COVID-19. On the other hand, in patients 
with Covid, however, new-onset diabetes and serious metabolic 
complications of pre-existing diabetes, such as diabetic ketoacidosis 
and hyperosmolarity, necessitating extremely high insulin doses, 
have been observed [7-9]. 
There have been potential mechanisms that may comprehend this 
relationship, especially between ongoing inflammation and insulin 
resistance [10]. Suffices to say, the COVID-19 virus has a very 
expeditious spreadability, and due to its contagious nature, 
influenza-related mortality is seen [11]. Evidence suggests that 
Diabetic patients tend to observe symptoms of either severe acute 
respiratory syndrome (SARS) or Middle East Respiratory Syndrome 
(MERS) but definitely not limited to the traditional symptoms 
observed [12, 13]. Such cases have been seen in India. Still, less 
acknowledged and known about as well as less studied [14]. 
Quantifiable data regarding the same can be obtained from the 
United Kingdom, the United States of America, and other first-world 
countries [15]. Developing countries have also produced substantial 
evidence, but it is yet subject to debate [16]. 
The study intends to incur fresh perspective and analysis, to 
conclude productive data on new-onset hyperglycemia, diabetic 
ketoacidosis, which was being increasingly described among post-
COVID-19 patients without a previous history of diabetes, albeit with 
no significant morbidity. The study assesses the underlying reasons 
for the increase in diabetes mellitus in post-COVID-19 recovered 
patients in a tertiary care hospital. 
METHODS AND MATERIALS 
The observational inductive retrospective study was conducted for a 
period of 4 mo, i.e., from December 2020 to April 2021, in a tertiary 
care hospital at Pune city in Maharashtra, India. The ethical 
clearance for the study was obtained from Bharati Vidyapeeth 
Deemed to be University Medical College (EC certificate no: 
BVDUMC/IEC/92). The study included subjects that recovered from 
SARS-Cov-2 and were treated post-Covid in the same studied 
hospital. The data was collected of such subjects whose glucose 
change was observed and confirmed by the Registered Medical 
Practitioner based on WHO, IDF, and ADA criteria [17]. 
The excluded subjects were either were not hospitalized due to 
COVID-19 or, before hospitalization, had an unstable glucose count. 
Considering these inclusion and exclusion criteria, the data of 25 
subjects were identified. The data of the identified subjects were 
obtained from the Department of Medical Records, separating them 
from subjects who did not fulfill the inclusion criteria. The data 
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collected encompassed demographic details of the subjects, the 
patient's comorbidities, the drugs prescribed, the clinical laboratory 
reports, the previous history of the patients, and the medication 
history. The mentioned information was being collected in a patient 
profile form. This patient profile form was prepared on the 
standardized technique offered by several studies on same and 
modified on pilot testing to qualify the need of the study [18]. The 
data obtained from the patient profile form was tabulated on the 
grounds of precision of the obtained data and evaluated with the 
research papers that had been established. These statistics helped 
analyze the data to identify the result. A co-relation was attempted 
between the drugs, the laboratory report, the history of the subject, 
and Covid — 19. The incidence rate was obtained from the 
traditional formula.  
Incident rate = [number of cases/number of patients admitted]x100 
RESULTS 
The present study was aimed to find out the incidence of diabetes 
mellitus in COVID-19 patients after the infection and its possible 
causes. A total of 5632 COVID-19 patients were admitted and treated 
for COVID-19 until the end of April 2021, and the records showed 694 
patients came for follow-up, of which 105 patients were re-admitted 
for some complications till March 2021. Of the remaining 589 patients, 
one patient who had a history of vertigo mentioned newly diagnosed 
Diabetes Mellitus, which the local general physician managed. 
Therefore, pre and post-COVID-19 hospitalization, only one follow-up 
patient had been seen with Newly Diagnosed Diabetes Mellitus. No 
special investigation was done on patients who came for follow-up in 
the out-patient-department since it was not a part of the study. 
Of the 105 patients who were admitted, 79 patients had Diabetes 
Mellitus. Among 105 patients, there were 11 patients, before COVID-
19 infection, who had no history of diabetes. Still, it developed as a 
complication after the treatment/discharge from Covid-19, for which 
the patients were re-admitted. Of which 65 patients had a history of 
diabetes mellitus, 14 of these observed sudden spikes in blood glucose 
level post-treatment, which was the reason for re-admission. 
The other complications (comorbidities) apart from Diabetes 
mellitus for which those 105 patients were admitted are depicted in 
table 1. 
 
Table 1: Complication during re-admission present in COVID-19 
patients 
Complications N [%] 
Abnormalities in ECG 2 
Chest pain 6 
Cough 9 
Difficulty in breathing 9 






Follow up 33 
High BP 6 
Hyperglycemic episode 3 
Joint or muscle pain 5 
Pneumonia 5 
 
It was observed that certain patients on admission did not have 
Diabetes Mellitus, which was confirmed by an on-admission clinical 
investigation, and physicians confirmed the diagnosis. The key 
findings of the same would be mentioned in a crux. Prednisolone 
was the only drug that was seen to have caused hyperglycemia. 
Secondly, persons above the age of 41 y developed Diabetes Mellitus. 
Thirdly, the incidence rate of persons who acquired Diabetes 
Mellitus after treatment of Covid-19 was 1.953/1000 persons in the 
tertiary care hospital. [11/5632 x 100 = 0.195%]. 
The demographic, clinical, and bacteriological profiles of patients re-
admitted after COVID-19 treatment (n=105) are outlined in table 2. 
 
Table 2: The demographic, clinical, and bacteriological profile of patients re-admitted after COVID-19 treatment (n=105) 
Parameters N  
AGE [mean±SD] 48.63±19.67 
Gender Male 75 % 
Female 25 % 
Hba1c [mean±SD] 6.21±0.86 
Hba1c on re-admission [mean±SD] 7.84±6.75 




Fatty liver 7 
Asthma 6 
Myt. Gravis 3 
Rheumatoid arthritis 3 






Co-infection E. Coli 9 
Klebsiella pneumonia 10 
Enterococcus faecium 2 
Enterococcus hominis 2 
Staphylococcus aureus 6 
Proteus mirabilis 4 
 
The male patients were found to be more prone to post-Covid 
Diabetes Mellitus than females. (Male: Female = 9:2) in the present 
study, more males had acquired diabetes mellitus after the COVID-
19 infections. Also, the patients with pre-existing comorbidities, 
such as cardiovascular disease and Rheumatoid Arthritis, were seen 
to have developed Diabetes Mellitus. The diagnosis of diabetes 
among these patients was made between the period of the 25th to 
the 40th day after their first discharge from the hospital. 
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On the contrary, some patients were admitted due to Covid-19 but 
possessed a history of Diabetes Mellitus. A certain number of these 
patients did see a spike or surge in the glucose levels after the 
treatment of Covid — 19. This surge or spike was controlled only by 
medical attention and insulin. Persons above the age of 47 y, who 
had a history of Diabetes Mellitus before hospitalization, observed 
this spike or surge. The demographic and laboratory findings in 
patients with sudden blood glucose spikes having a history of 
diabetes mellitus are listed in table 3. The incidence rate of persons 
whose blood glucose level observed a surge or spike after the 
treatment of Covid-19 was 13.33/1000 persons in the tertiary care 
hospital. (14/105 x 100 = 13.333%) 
 
Table 3: The demographic and laboratory findings in patients with sudden blood glucose spikes having a history of diabetes mellitus 
Parameters With a history of DM (N=76) 
Age [mean±SD] 58±10.27 
Gender Male 61 
Female 15 
Hba1c [mean±SD] 6.42±0.71 
Hba1c on re-admission [mean±SD] 8.55±7.80 
History of  Hypertension 19 
Pneumonia 27 
IHD 7 
Fatty liver 7 
Asthma 5 
Myt. Gravis 3 
Rheumatoid arthritis 1 






Co-infection E. Coli 7 
Klebsiella pneumonia 9 
Enterococcus faecium 2 
Enterococcus hominis 1 
Staphylococcus aureus 5 
Proteus mirabilis 4 
The Co-infection findings in patients with newly diagnosed diabetes mellitus and patients with sudden blood glucose spikes having a history of 
diabetes mellitus are tabulated in table 4. 
 
Table 4: The Co-infection findings in patients newly diagnosed with diabetes mellitus and patients with sudden blood glucose spikes 
having a history of diabetes mellitus 
 Organism With newly diagnosed DM, covid-19 patients 
(n=11) N  
With a history of DM, covid-19 patients (n=14) 
N  
Co-infection E. Coli 2 3 
Klebsiella pneumonia 3 1 
Staphylococcus hominis 1 0 
Staphylococcus aureus 1 0 
Proteus mirabilis 0 1 
Enterococcus faecium 0 1 
 
DISCUSSION 
Empathy from the international media surges towards India. 
Looking onto the administration, India sulks to save lives. Hence, the 
Indian scenario of Covid-19 draws international attention [19, 20]. 
The repercussion of COVID-19 infection has been a subject matter of 
debate and discussion. There have been several studies working on 
this matter and several more yet to publish. Most drugs used during 
Covid–19 were already in used in the market. There is a lack of 
studies to claim the side effects of these drugs causing a metabolic 
disorder, especially in classical antivirals and steroids where the 
patients have shown improvement after hospitalization. An animal 
study on cats proved that prednisolone induced diabetes mellitus 
when used over a long period [21]. This may indicate that a 
particular category of patients is susceptible to induced diabetes 
mellitus. This is a similar trend observed where Mucormycosis due 
to prednisolone's immunocompromising nature. The probable 
mechanism of action could be that in human monocytes, elevated 
glucose levels directly increase SARS-CoV-2 replication, while glycol 
sis supports SARS-CoV-2 replication by generating mitochondrial 
reactive oxygen species and hypoxia-induced factor l α activation. 
Therefore, high blood sugar can cause the virus to spread. Consistent 
with this hypothesis, it has been established that hyperglycemia or 
the history of TIDM and T2DM are independent predictors of the 
morbidity and mortality of SARS patients [10]. In addition, the 
simultaneous use of T2DM in MERS-CoV-infected mice can cause 
immune response disorders, which can lead to severe immune 
responses and a wide range of lung diseases. Diabetic patients usually 
have a higher severity of SARS-CoV-2 infection than non-diabetic 
patients, and poor blood sugar control indicates higher drug doses, 
hospital needs and mortality [15]. SARS Covid-19 infections may act as 
worsening causes for diabetic patients. As mentioned, it can be due to 
acute metabolic complications by the effect on ß-cell functioning. This 
effect on p-cell functioning may cause several disorders diabetic 
ketoacidosis, hyperglycemia in individuals with unknown history of 
diabetes, and potentially new-onset Diabetes [23]. 
Several post-Covid hospitalization issues are pulsing around. These 
include non-restorative sleep, chronic fatigue syndrome, cognitive 
dysfunction, autonomic dysfunction, etc. These all could be termed 
as 'POST-COVID SYNDROME' [24]. As per the International Diabetes 
Federation (IDF) Diabetes Atlas, the prevalence of diabetes Mellitus 
above the age of 19 and below 80 y is 6.6% (The year 2010). India, 
also known as the Diabetes capital of the world, holds an estimate of 
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50.8 million people suffering from the same as of 2010 [25]. 
Diabetes has been a concern since its discovery. The discovery of 
Covid-19 has simply worsened it.  
The study tried to look into the presence of both simultaneously as 
well the upcoming Diabetes post-COVID-19 hospitalizations. A 
symbolic link could be a metabolic disturbance that may be caused 
due to the Covid-19 infection-a metabolic disorder that lasts 
probably a lifetime. The body has not yet recovered from the 
damage after being tested Covid-19 negative. It is only after 45 d 
that there may be less possibility of this physical health crisis. 
Usually, patients are called for follow-up after 30 d. This practice is 
now scientifically more explicit than before. Patients may observe 
poor health during a specific phase post-Covid. It should be highly 
recommended to the patient's caretakers that the post-covid phase 
is equally crucial as Covid 19 positive phase. 
Regarding infections, it would also be a possibility that due to several 
drugs having an interaction, there is the presence of newly diagnosed 
Diabetes Mellitus or diabetes spike. We can observe a mono-
directional relationship in polypharmacy and diabetes mellitus leading 
to infection susceptibility [26]. There is no observed relationship 
between acquisition of a bacterial infection and Diabetes Mellitus on 
further investigation of both these categories. Still, it is evident that 
patients who have DM are more susceptible to infection [27].  
Prednisolone is a drug through which a glucose spike is observed during 
the course of its administration, but once the drug is withdrawn, this 
spike is not observed any further after the wash-off period [28, 29]. BMI 
of every subject was obtained to establish a relationship between BMI 
and Covid-19, and an association was observed [30]. The analysis 
reports an association between Obesity with the possibility of 
acquisition or spike in diabetes Mellitus [31, 32]. It cannot be denied that 
the key attention for this permanent diabetes mellitus is on steroids due 
to its well-known symptom of hyperglycemia. 
Substantial literature claims that several drugs may have interacted 
and caused a metabolic disorder, but prednisone might have been 
the key drug [33]. The right conditions for metabolic disease are age, 
weight, diet, and other physical and environmental factors. Since DM 
has a bidirectional relationship with COVID–19, maybe an added-on 
factor to these conditions [34]. Considering this bi-directionality in 
COVID-19, there is a possibility that this bi-directionality may have 
also been reflected in metabolic disorders, i.e., Diabetes Mellitus, as 
seen in the case of mucormycosis [35]. A spike in the patient's 
glucose levels who required hospitalization may have been due to a 
possible result of the unfavorable outcomes. 
CONCLUSION 
Patients may have acquired DM or observed a spike due to steroids, 
but this may have become a permanent condition due to the ongoing 
health-related quality of life of the patient. It can also be kept open 
as a possibility that several drugs may have interacted under the 
'favorable' conditions for a metabolic disorder. 
Further investigation must be insisted on the use of steroids in 
patients with Covid-19. The medical fraternity is liable when is a 
disease occurs due to a drug–iatrogenesis. Changes in the formulary 
and the line of treatment is essential.  
Since the incidence rate is minuscule but adequate, which means 
that probably the event is happening, but it is not given enough 
attention. The guidelines for non-communicable diseases, especially 
DM, need to be reviewed by the Indian Council of Medical Research 
concerning Covid-19.  
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